Search by Algolia
Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Apollo Global Management, Inc.Apollo Global Management Reports Second Quarter 2025 Financial Results
NORTECH SYSTEMS INCNortech Systems Reports Decline in Q2 2025 Financial Performance
Rapport Therapeutics, Inc.Rapport Therapeutics Reports $26.7 Million Net Loss in Q2 2025, Driven by Increased R&D Expenses
Sunrise Realty Trust, Inc.Sunrise Realty Trust Reports 241% Revenue Growth and Increased Net Income in Latest Quarter
Vital Farms, Inc.Vital Farms Reports 25% Revenue Growth to $184.8 Million in Latest 10-Q Filing
REGENXBIO Inc.REGENXBIO Reports Q2 2025 Financial Results with $21.4M Revenue and $70.9M Net Loss
SAB Biotherapeutics, Inc.SAB Biotherapeutics Reports $10.1 Million Net Loss in Q2 2025, Seeks Funding for Clinical Trials
Verano Holdings Corp.Verano Holdings Reports Q2 2025 Financial Results with $202.3M Revenue and Net Loss of $19.2M
Amylyx Pharmaceuticals, Inc.Amylyx Pharmaceuticals Reports $41.4 Million Net Loss in Q2 2025, Focuses on Clinical Pipeline
C4 Therapeutics, Inc.C4 Therapeutics Reports $26M Net Loss in Q2 2025, Revenue Declines
Phathom Pharmaceuticals, Inc.Phathom Pharmaceuticals Reports $39.5M Product Revenue in Q2 2025, Faces $75.8M Net Loss
KALTURA INCKaltura Reports Q2 2025 Financial Results with $44.5M Revenue and Improved Net Loss
Cartesian Therapeutics, Inc.Cartesian Therapeutics Reports Q2 2025 Revenue Decline to $298,000 Amid Increased Operating Expenses
Monte Rosa Therapeutics, Inc.Monte Rosa Therapeutics Reports $23.2M Collaboration Revenue and $12.3M Net Loss for Q2 2025
Liberty Latin America Ltd.Liberty Latin America Reports Revenue Decline and Significant Operating Loss in Q2 2025
Cullinan Therapeutics, Inc.Cullinan Therapeutics Reports $70.1 Million Net Loss in Q2 2025
1stdibs.com, Inc.1stdibs.com Reports Slight Decline in Q2 2025 Net Revenue, Net Loss of $4.3 Million
DraftKings Inc.DraftKings Reports 36.9% Revenue Growth to $1.51 Billion in Q2 2025
Black Diamond Therapeutics, Inc.Black Diamond Therapeutics Reports $45.98 Million Net Income and Advances Silevertinib in Latest 10-Q
Avalo Therapeutics, Inc.Avalo Therapeutics Reports $33.9 Million Net Loss and Increased R&D Expenses for First Half of 2025
PAPA JOHNS INTERNATIONAL INCPapa John’s Reports 4.2% Revenue Growth in Q2 2025, Faces Decline in Net Income
Immunocore Holdings plcImmunocore Reports 30% Revenue Growth to $97.964 Million in Q2 2025
Chicago Atlantic Real Estate Finance, Inc.Chicago Atlantic Real Estate Finance Reports Q2 2025 Financial Results with $8.9M Net Income
INSMED IncInsmed Reports 18.9% Revenue Growth to $107.4 Million in Q2 2025
STARWOOD PROPERTY TRUST, INC.Starwood Property Trust Reports Q2 2025 Financial Results with Revenue Decline and Increased Net Income